芪胶升白胶囊联合重组人粒细胞集落刺激因子治疗气血两虚型化疗后白细胞减少症临床研究  

Clinical Study on the Efficacy of Astragalus and Colla Corii Asini Capsules for Increasing White Blood Cells Combined with Recombinant Human Granulocyte Colony Stimulating Factor in Treating Chemotherapy-Induced Leukopenia with Qi-Blood Deficiency Syndrome

作　　者：刘君 胡敏 袁明霞 潘连生 胡林飞 齐继鹏 LIU Jun;HU Min;YUAN Mingxia;PAN Liansheng;HU Linfei;QI Jipeng(Xinyu Hospital of Traditional Chinese Medicine,Xinyu,Jiangxi,China,338000)

机构地区：[1]新余市中医院,江西新余338000

出　　处：《河南中医》2024年第12期1893-1897,共5页Henan Traditional Chinese Medicine

基　　金：新余市科技计划项目(20233090940)。

摘　　要：目的:观察芪胶升白胶囊联合重组人粒细胞集落刺激因子(recombinant human granulocyte colony stimulating factor,rhG-CSF)治疗化疗后气血两虚型白细胞减少症的临床疗效。方法:选取新余市中医院2022年3月至2023年3月治疗的化疗后白细胞减少症患者128例,按照随机数字表法分为对照组和试验组,每组64例。两组患者化疗后外周血白细胞(white blood cell,WBC)<4.0×10^(9) L^(-1)时,对照组化疗结束24 h内使用rhG-CSF注射液治疗,试验组在对照组治疗的基础上给予芪胶升白胶囊口服治疗。观察两组患者治疗前后CD3^(+)、CD8^(+)、CD4^(+)、CD4^(+)/CD8^(+)、超敏C反应蛋白(hs-C reactive protein,hs-CRP)、肿瘤坏死因子(tumor necrosis factor,TNF)-α、白细胞介素(interleukin,IL)-6、白细胞计数(white blood cell,WBC)、血红蛋白(hemoglobin,Hb)、血小板计数(platelet,PLT)变化情况及感染次数、抗生素使用时间、rhG-CSF使用量和时间、临床疗效、不良反应。结果:两组治疗后CD3^(+)、CD8^(+)、CD4^(+)、CD4^(+)/CD8^(+)均上升,且试验组高于对照组,差异有统计学意义(P<0.05);两组治疗后TNF-α、IL-6、hs-CRP水平均降低,且试验组低于对照组,差异具有统计学意义(P<0.05);试验组感染情况、抗生素使用时间、rhG-CSF使用量和时间低于对照组,差异有统计学意义(P<0.05);试验组有效率为81.25%,对照组有效率为71.88%,试验组有效率高于对照组,差异具有统计学意义(P<0.05);对照组发生不良反应15例,不良反应发生率为23.44%,试验组发生不良反应6例,不良反应发生率为9.38%,试验组低于对照组,差异具有统计学意义(P<0.05)。结论:芪胶升白胶囊联合rhG-CSF可使化疗后气血两虚型白细胞减少症患者白细胞水平升高,减轻炎症,降低不良反应发生率。Objective:To observe the clinical efficacy of Astragalus and Colla Corii Asini Capsules for Increasing White Blood Cells combined with recombinant human granulocyte colony stimulating factor(rhG-CSF)on chemotherapy-induced leukopenia with qi-blood deficiency syndrome.Methods:A total of 128 patients with chronic renal failure combined with renal anemia treated at Xinyu Hospital of Traditional Chinese Medicine from March 2022 to March 2023 were selected.They were randomly divided into the control group and the test group,with 64 cases in each group.When the peripheral blood white blood cell count(WBC)was<4.0×10^(9) L^(-1) after chemotherapy,the control group received rhG-CSF injection within 24 hours after chemotherapy,while the test group received Astragalus and Colla Corii Asini Capsules for Increasing White Blood Cells orally in addition to rhG-CSF.The changes in CD3^(+),CD8^(+),CD4^(+),CD4^(+)/CD8^(+),high-sensitivity C-reactive protein(hs-CRP),tumor necrosis factor(TNF)-α,interleukin(IL)-6,WBC,hemoglobin(Hb),platelet count(PLT),infection frequency,antibiotic usage time,rhG-CSF dosage and duration,clinical efficacy,and adverse reactions were observed in both groups before and after treatment.Results:After treatment,CD3^(+),CD8^(+),CD4^(+),CD4^(+)/CD8^(+)increased in both groups,with the test group showing significantly higher levels than those of the control group,and the differences were statistically significant(P<0.05).TNF-α,IL-6 and hs-CRP levels decreased in both groups,and the test group had significantly lower levels than those of the control group,and the differences were statistically significant(P<0.05).The test group had lower infection rates,antibiotic usage time,rhG-CSF dosage,and duration compared to the control group,and the differences were statistically significant(P<0.05).The clinical efficacy rate was 81.25%in the test group and 71.88%in the control group respectively,with the test group showing a significantly higher efficacy rate,and the difference was statistically significant(P<0.05).A

关 键 词：化疗后白细胞减少症 芪胶升白胶囊 重组人粒细胞集落刺激因子 气血两虚 白细胞 T淋巴细胞 

分 类 号：R273.571[医药卫生—中西医结合]